TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00565175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: famotidine
Description: Capsules containing 100 mg of famotidine p.o., twice daily for 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Microcrystallized cellulose)
Description: Placebo administered in identical capsules as the experimental drug.
Study: NCT03749408

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine plus mannitol
Description: local anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine alone
Description: local anesthesia
Study: NCT00154843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lycopene
Description: A: Lycopene15 mg/day ; B: Lycopene30 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lycopene
Description: A: Lycopene15 mg/day ; B: Lycopene30 mg/day
Study: NCT00849290

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: APC8015F
Description: APC8015F is an autologous active cellular immunotherapy product designed to stimulate an immune response against prostate cancer. APC8015F consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), that have been activated in vitro with a recombinant fusion protein.
Study: NCT03463252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: MPA oral 250mg-500mg qd for 3 months per cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: MPA oral 250mg-500mg qd for 3 months per cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: MPA oral 250mg-500mg qd for 3 months per cycle

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mirena®
Description: levonorgestrel intrauterine sustained release system (LNG-IUS) placed in uterus for 3 months per cycle

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mirena®
Description: levonorgestrel intrauterine sustained release system (LNG-IUS) placed in uterus for 3 months per cycle

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mirena®
Description: levonorgestrel intrauterine sustained release system (LNG-IUS) placed in uterus for 3 months per cycle

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mirena®
Description: levonorgestrel intrauterine sustained release system (LNG-IUS) placed in uterus for 3 months per cycle

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mirena®
Description: levonorgestrel intrauterine sustained release system (LNG-IUS) placed in uterus for 3 months per cycle

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mirena®
Description: levonorgestrel intrauterine sustained release system (LNG-IUS) placed in uterus for 3 months per cycle

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mirena®
Description: levonorgestrel intrauterine sustained release system (LNG-IUS) placed in uterus for 3 months per cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH agonist
Description: GnRH-a intramuscular injection 3.75mg once a month for 3 months per cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH agonist
Description: GnRH-a intramuscular injection 3.75mg once a month for 3 months per cycle
Study: NCT02629042

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partial endodontic treatment under local and/or locoregional anesthesia
Description: The reference management consists in local and locoregional anesthesia of the molar and partial endodontic treatment. At the end of the emergency visit, all the patients, whatever their randomization group, will be given two types of antalgics and will be recommended to take them only if they have pain. Seventy-two hours after, all the patients, whatever their randomization will have endodontic treatment under local and locoregional anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisolone
Description: The evaluated intervention consists in per-os administration of prednisolone (1 mg / kg) during the emergency visit followed-up by one morning dose by day during three days. At the end of the emergency visit, all the patients, whatever their randomization group, will be given two types of antalgics and will be recommended to take them only if they have pain. Seventy-two hours after, all the patients, whatever their randomization will have endodontic treatment under local and locoregional anesthesia.
Study: NCT01129804

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping Skills Training
Description: Patients in both treatments will be taught skills to help them keep from drinking.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coping Skills Training
Description: Patients in both treatments will be taught skills to help them keep from drinking.
Study: NCT03538704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin is given to patients 1-1.5g/d.
Study: NCT03371056

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacteriological analyses on clinical samples performed with swabs
Description: Bacteriological analyses will be performed to assess the InSPIRe kit

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacteriological analyses on clinical samples performed with swabs
Description: Bacteriological analyses will be performed to assess the InSPIRe kit

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacteriological analyses on clinical samples performed with swabs
Description: Bacteriological analyses will be performed to assess the InSPIRe kit

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacteriological analyses on clinical samples performed with swabs
Description: Bacteriological analyses will be performed to assess the InSPIRe kit
Study: NCT02347072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFF MDI (PT003)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MDI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spiriva® Respimat® (Tiotropium Bromide)
Description: Tiotropium Bromide Inhalation Solution; Spiriva® Respimat® (Spiriva)
Study: NCT04235842

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: Moderate-intensity continuous exercise training performed at cycle ergometer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity interval training performed at cycle ergometer.
Description: High-intensity interval training performed at cycle ergometer.
Study: NCT02131116

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Metacognitive Therapy
Description: Integrated Metacognitive Therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: Treatment as Usual
Study: NCT01660802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 700 μg Dexamethasone
Description: 700 μg Dexamethasone intravitreal injection in the study eye on Day 1.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 700 μg Dexamethasone
Description: 700 μg Dexamethasone intravitreal injection in the study eye on Day 1.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham administered in the study eye on Day 1.
Study: NCT00934232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan (Bu) is a bifunctional alkylating agent currently used almost exclusively as a component of conditioning regimens for both autologous and allogeneic stem-cell transplants.
Study: NCT03809325

Intervention type: DRUG
Intervention: Paliperidone Palmitate 3-Month Formulation (PP3M)
Description: No intervention will be administered as a part of this study. Participants who have been treated with PP3M in clinical practice will be enrolled.
Study: NCT02774187

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: administration of Sorafenib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: administration of Sorafenib
Study: NCT00794924

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: VSL#3
Description: one sachet per day, for 45 consecutive days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VSL#3
Description: one sachet per day, for 45 consecutive days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one sachet per day, for 45 consecutive days
Study: NCT02718222

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Post-partum IUD
Description: The PPIUD intervention aims to address the postpartum contraceptive needs of women by training community midwives, health workers, doctors and delivery unit staff in postpartum IUD counselling and insertion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Post-partum IUD
Description: The PPIUD intervention aims to address the postpartum contraceptive needs of women by training community midwives, health workers, doctors and delivery unit staff in postpartum IUD counselling and insertion.
Study: NCT00763451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide (AVE0010)
Description: Self-administered by subcutaneous injections once daily within the hour preceding breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide (AVE0010)
Description: Self-administered by subcutaneous injections once daily within the hour preceding breakfast.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Self-administered by subcutaneous injections once daily within the hour preceding breakfast.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Self-administered by subcutaneous injections once daily within the hour preceding breakfast.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pen auto-injector

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pen auto-injector

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Pen auto-injector

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Pen auto-injector

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
Study: NCT00348387

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Poliomyelitis Vaccine inactivated
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Poliomyelitis Vaccine in Dragee Candy (Human Diploid Cell)
Description: 1g dragee, oral
Study: NCT01383330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: megace
Description: 800mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DW-ES(A)
Description: 625mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DW-ES(B)
Description: 625mg
Study: NCT00603811

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAX102 [Flagellin.HuM2e]
Description: dose ranging, 2 i.m. doses given 28 days apart

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03557606

Intervention type: PROCEDURE
Intervention: Alar treatment with BMC using anterior approach
Description: Patients with CCJ instability will undergo a bone marrow aspiration of approximately 30-60 cc. Platelet rich plasma (PRP) and platelet lysate (PL) will be derived from the bone marrow aspirate and later mixed with the bone marrow cell layer. While under TIVA anesthesia, the injectate is then injected under fluoroscopy into the area in need of treatment using an anterior approach through the posterior oropharynx with direct visualization of the injection site via endoscopy. The alar, transverse, and accessory ligaments are the target areas to be treated with the bone marrow concentrate.
Study: NCT00727506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Description: BIBW 2992 once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TMZ
Description: TMZ 21/28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992 plus TMZ
Description: BIBW 2992 once daily plus TMZ 21/28 days
Study: NCT01030432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-650032
Description: Tablets, Oral, 200 mg, Twice Daily, 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-650032
Description: Tablets, Oral, 200 mg, Twice Daily, 12 or 24 weeks, depending on response

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0 mg, twice daily, 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets, Oral, 0 mg, twice daily, 0 or 12 weeks (depending on response) beginning at Week 12

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0 mg, twice daily 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alfa-2a
Description: Syringe, Subcutaneous injection, 180 mcg / 0.5 mL, Weekly, 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Peginterferon Alfa-2a
Description: Syringe, Subcutaneous injection, 180 mcg / 0.5 mL, Weekly, 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Peginterferon Alfa-2a
Description: Syringe, Subcutaneous injection, 180 mcg / 0.5 mL, Weekly, 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alfa-2a
Description: Syringe, Subcutaneous injection, 180 mcg / 0.5 mL, Weekly, 24 or 48 weeks, depending on response

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablet, Oral, 500 or 600 mg based on weight, Twice Daily, 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin
Description: Tablet, Oral, 500 or 600 mg based on weight, Twice Daily, 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin
Description: Tablet, Oral, 500 or 600 mg based on weight, Twice Daily, 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablet, Oral, 500 or 600 mg based on weight, Twice Daily, 24 or 48 weeks depending on response
Study: NCT01035541

Intervention type: DEVICE
Intervention: PiCCO® Monitoring
Description: Fluid and vasopressor management according to PiCCO measruements

Intervention type: DEVICE
Intervention: PiCCO® Monitoring
Description: Fluid and vasopressor management according to PiCCO measruements
Study: NCT02498236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal Oxytocin
Study: NCT01228877

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: Adduction, Abduction and Squat exercise three times a week for 16 weeks
Study: NCT03031210

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: (90 mg/kg/day) twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: (90 mg/kg/day) twice daily
Study: NCT02078492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg of Ketorolac
Description: Patients will receive 10 mg of Ketorolac for pain control.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15 mg of Ketorolac
Description: Patients will receive 15mg of Ketorolac for pain control.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg of Ketorolac
Description: Patients will receive 30mg of Ketorolac for pain control.
Study: NCT06394609

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: double loaded knotted suture anchor
Description: arthroscopic bankart repair by using double loaded knotted suture anchor

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: double grand knot
Description: arthroscopic bankart repair by using double grand knot
Study: NCT00383123

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix™
Description: Subjects were administered 1 or 2 doses\* intramuscularly, into the non-dominant upper arm for children \> 12 months of age, in the anterolateral thigh for children \< 12 months.~\*Only those subjects between the age of 6 months and \< 9 years, who had no history of prior influenza vaccination, received 2 doses at months 0 \& 1.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone
Description: Subjects were administered 1 or 2 doses\* intramuscularly, into the non-dominant upper arm for children \> 12 months of age, in the anterolateral thigh for children \< 12 months.~\*Only those subjects between the age of 6 months and \< 9 years, who had no history of prior influenza vaccination, received 2 doses at months 0 \& 1.
Study: NCT03230825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral contraceptive
Description: Daily oral contraceptive agent for 3 weeks (FLAME, containing 0.02 mg Ethinylestradiol and 0.075 mg Gestodene)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Expectant management
Description: No intervention and a follow up visit a wewk later
Study: NCT00544232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin, paclitaxel, cyclophosphamide, Methotrexate, 5 FU, darbepoetin alfa
Description: Epirubicin (90 mg/m2) d1, q21d - 4× / cyclophosphamide (600 mg/m2) d1, q21d - 4× followed by paclitaxel (175 mg/m2) d1, q21d - 4×~+/- Darbepoetin alfa 1 × 4.5 μg/kg of body weight every two weeks with the start of the first epirubicin dose (day 1) to 14 days after the last dose of paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa
Description: Epirubicin (150 mg/m2) d1, q14d - 3× followed by paclitaxel (225 mg/m2) d1, q14d - 3×, followed by CMF d1/d8, q28d - 3× Obligatory pegfilgratim 6 mg, subcutaneous injection on day 2 after epirubicin and/or paclitaxel and secondary prophylactic dose after CMF~+/- Darbepoetin alfa 1 × 4.5 μg/kg of body weight every two weeks with the start of the first dose of epirubicin (day 1) until 14 days after the last dose of CMF
Study: NCT02760901

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: patients received acetazolamide 250 mg half an hour before cisplatin with saline hydration.for prevention of cisplatin nephrotoxicity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylcysteine
Description: patients received NAC (600 mg every 12 hours) for 4 doses beginning 24 hours before cisplatin with saline hydration.for prevention of cisplatin nephrotoxicity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mannitol
Description: patients received mannitol 20 % 100 ml half an hour before cisplatin and saline hydration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: saline hydration 2500 ml before cisplatin therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: saline hydration 2500 ml before cisplatin therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: saline hydration 2500 ml before cisplatin therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: patients with tumours already prescribed cisplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: patients with tumours already prescribed cisplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: patients with tumours already prescribed cisplatin
Study: NCT02683499

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasonic tips
Description: These tips are going to be used to give the final shape of the prepared surfaces before taking the impression for the construction of the veneers.
Study: NCT00455741

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol infusion
Description: Graded estradiol infusion of 0.1 mcg/kg/hr for 12 hr, 0.135 mcg/kg/hr for 12 hr, 0.165 mcg/kg/hr for 12 hr and 0.2 mcg/kg/hr for 60 hr.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol infusion
Description: Graded estradiol infusion of 0.1 mcg/kg/hr for 12 hr, 0.135 mcg/kg/hr for 12 hr, 0.165 mcg/kg/hr for 12 hr and 0.2 mcg/kg/hr for 60 hr.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone infusion
Description: Progesterone infusion of 4.77 nmol/kg/hr (1.5 mcg/kg/hr) for 24 hr and 6.36 nmol/kg/hr (2 mcg/kg/hr) for the final 24 hr of the 5-day study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone infusion
Description: Progesterone infusion of 4.77 nmol/kg/hr (1.5 mcg/kg/hr) for 24 hr and 6.36 nmol/kg/hr (2 mcg/kg/hr) for the final 24 hr of the 5-day study.
Study: NCT04699760

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish Oil
Description: 8 weeks, 2.2 G EPA/day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03028597

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Values Affirmation
Description: Participants are asked to circle the two or three values that are MOST important to them. Next, participants are asked to think about times when the values chosen might be important to THEMSELVES and then write a few sentences to describe when and why they might be important.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Values Affirmation
Description: Participants are asked to circle the two or three items that are LEAST important to them. Next, participants are asked to think about times when the values chosen might be important to SOMEONE ELSE and then write a few sentences to describe when and why they might be important.
Study: NCT01160627

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydration
Description: Saline hydration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylcysteine
Description: Acetylcystein tablets for 2 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium bicarbonate
Description: Sodium bicarbonate 500 ml followed by 100 ml/hour for 5 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined Acetylcystein and Sodium Bicarbonate
Description: Sodium bicarbonate 500 ml followed by 100 ml/hour for 5 hours combined with acetylcystein tablets for 2 days